

CONVENTIONAL DRUGS AND HERBAL MEDICINES-INDUCED HEPATOTOXICITY

Kamal E. H. EL-Tahir ^{1*}, Othman A. Gubara ² and AbdulRahman M. Ageel¹

تهدف هذه المراجعة إلى تنوير كل من الأطباء والصيادلة وجميع العاملين في المهن الطبية عن قدرة بعض الأدوية المشيدة معملياً والمصنعة من بعض النباتات الطبية المتواجدة في الأسواق بأشكال صيدلانية ممتازة ويتم استعمالها في بلادنا والبلاد الأخرى بكثرة. وتبدأ هذه المراجعة بإعطاء القارئ فكرة عن انتشار التسممات الكبدية الحديثة بهذه الأدوية في بعض الأقطار ثم تعطي وصفاً عن مختلف وظائف الكبد ومن ثم تتولى مناقشة آليات فعل بعض الأدوية والنباتات الطبية والذي من خلاله تقوم هذه الكيماويات بحفز وإحداث تسمم كبدية تحسسي وإزعاجات أخرى مثل داء الصفراء والتهابات الكبد الحبيبية والتشمم الفسفوري والتهابات الكبد الدهنية والتليف والتشمم الكبدية والأورام الخبيثة. اهتمت هذه المراجعة بإعطاء أمثلة متعددة للأدوية المشيدة معملياً وللنباتات الطبية ذات القدرة على إحداث نوع أو أنواع متعددة من التسممات الكبدية. وعند ذكر النباتات الطبية تم ذكر الأسماء اللاتينية والتجارية للنبات وعائلته النباتية واستعمالاته الطبية والمكونات الفعالة في النبات المسئولة عن إحداث وحفز التسممات الكبدية. وأشارت هذه المراجعة أيضاً إلى الطرق المتبعة المتوفرة لتشخيص أسباب التسمم الكبدية والإمكانات المتاحة لعلاجها. وتلفت هذه المراجعة المصغرة الانتباه إلى أن سحب ومنع تداول هذه الأدوية والنباتات الطبية، والتي لديها القدرة على إحداث تسممات كبدية من التسجيل الصيدلي، لا يعيق مسيرة علاج الأمراض التي تستعمل من أجلها هذه الأدوية والنباتات الطبية.

involved in the medical field with the abilities of various synthetic drugs and medicinal plants-that are formulated in various elegant pharmaceutical forms-that are circulating in both our own countries and abroad. It initially gives an idea about the prevalence of drugs-induced hepatotoxicity in some countries and then it describes the various physiological functions of the liver. It also discusses the various mechanisms through which chemicals induce toxic and allergic hepatotoxicity and other disturbances such as cholestasis, granulomatous hepatitis, phospholipidosis, steatohepatitis, fibrosis, cirrhosis and tumors. For each of these diseases numerous examples of synthetic drugs and medicinal plants are given. With regard to medicinal plants, the Latin and Trade names, botanical families, uses and active constituents responsible for the induction of the hepatotoxicity are also given. The possible methods available for diagnosis and treatment of such diseases are given. The review then draws the attention to the fact that withdrawal of these drugs and medicinal plants from the pharmaceutical register does not limit the effective treatments of the various diseases for which these chemicals are indicated.

Introduction

The liver performs numerous functions including bile formation and secretion, synthesis of a range of proteins including clotting factors, detoxification of drugs, xenobiotics and endogenous compounds,

storage of vitamins, minerals and regulation of blood glucose. It consists of four main types of cells. The hepatocytes are the biosynthetic engines of the liver. Their important Golgi system and rough endoplasmic reticulum allow them to synthesize and secrete an array of proteins and metabolic enzymes. The endothelial cells line the sinusoids and serve as a barrier between the blood and hepatocytes. Two additional cell types line the sinusoids: They include Kupffer's cells, which are capable of removing and phagocytizing old and defective blood cells, bacteria and other foreign materials, and Stellati cells, which

¹*Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.²Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

*To whom correspondence should be addressed.

store fat and vitamin A (1).

According to literature surveys several drugs have been implicated in cases of hepatic injury (2). Among the therapeutic classes most often involved in hepatotoxicity are neurological drugs, followed by cardiovascular drugs, antibacterial drugs and those affecting metabolism and musculoskeletal system (3).

Reports in the literature showed that incidences of hepatotoxicity associated with drug use accounted for 10.7% in USA (4), 2.85% in United Kingdom (5), 4.2% New Zealand (6) and 9.7% in France (3). Nowadays complementary alternative medicine is increasingly used in various parts of the world. It includes dietary, nutritional and life styles changes together with a separately mind and body control measures, cauterization, manual healing and biological treatments with animal, sea and herbal products. The latter are produced in various pharmaceutical forms including pills, capsules, tablets, powders, syrups and suppositories. Of all the alternative medicines, herbal products are gaining wide spread popularity for two reasons. Firstly, their production and presentation to the public in elegant pharmaceutical forms that resemble the synthetic and well-studied pharmaceutical products, and secondly to the purported mistaken belief that herbal medicines are natural and bear no harm or toxicity to the human body. However, it should always be remembered that some herbal therapies are really toxic and can induce hepatotoxicity or even death. It should be noted that, for instance, in Asiatic countries, where some statistics are reported, herbal medicines-induced hepatotoxicity reached 30% of all reported drug-induced liver diseases (7). This review will present some evidence regarding this aspect.

Biotransformation of drugs in the liver:

The liver's unique metabolism makes it an important target of the toxicity of drugs and xenobiotics. Most of these compounds enter the body through the gastrointestinal tract with minority absorbed directly through the lung or skin or by parenteral route. The greater part of drugs and xenobiotics are lipophilic, and can easily cross the membrane of intestinal and the hepatocyte cells. Drugs are rendered more hydrophilic by enzymatic action in the hepatocyte, yielding water-soluble products that are excreted in the urine or bile (8). The pathways of drug metabolism can be classified as either phase I reactions (i.e. oxidation, reduction

and hydrolysis) mediated by various cytochrome P450 isozymes, and/or phase II conjugation (i.e. glucuronidation, acetylation, sulphation and methylation), mediated by a variety of transferases. For highly polar drugs such metabolism is unnecessary. Some drugs may break down spontaneously. In most instances, metabolites generated by means of these reactions are either pharmacologically inactive or highly reactive. Based on their chemical character these metabolites may bind covalently to cellular macromolecules resulting in the formation of toxic oxygen species or react with membrane lipids to form lipid peroxides (9).

Other metabolic pathways for biotransformation of many compounds involve glutathione and possibly other antioxidants (e.g. vitamin E and ascorbic acid). Glutathione is a thiol-containing tripeptide capable of binding to potentially harmful electrophilic compounds through glutathione-S-transferase, and thus plays an important role in protecting the cell from these toxic species (10). Likewise, altered pharmacokinetics variables resulting from genetic influences, sex, age, and other conditions such as diabetic, hepatic and renal diseases may influence the metabolic outcomes, and predispose patients to toxic reactions to many drugs (11-13). Multiple factors are also often implicated, the most frequently being enzyme induction. Common inducing agents of certain P450 enzymes include phenobarbital, phenytoin, rifampicin as well as cigarette smoking.

Pathogenesis of hepatotoxicity:

Drug or herbal medicines-induced hepatic damage is divided into several types that include:

a. Toxic hepatic damage:

This type of damage is initiated via the interaction of the drug or the active component(s) of the herb with hepatic cytochrome P450 enzymes to produce electrophilic molecules or oxygen radicals that interact with the hepatic cells membranes and/or enzymes leading to the damage and necrosis of the hepatocytes (10,14). In addition, the drug may act to elevate the intracellular Ca^{2+} concentration resulting in damage of the hepatic mitochondria and the membranes integrity (10).

The classical example of such hepatic damage is that produced by high doses of paracetamol (acetaminophen) (15). The normal metabolism of the therapeutic doses of paracetamol involves sulphate

conjugation via glutathione and excretion in the urine (16). However, following acute or chronic consumption of high doses of paracetamol, the normal conjugation pathway is exhausted due to the depletion of glutathione and another cytochrome P450-pathway operates to produce a toxic highly reactive metabolite *N*-acetyl-*p*-benzoquinoneimine (NABQI). The latter interacts covalently with protein molecules in the hepatocytes leading to cell degeneration and death (15-17). Paracetamol-induced hepatotoxicity is characterized by very high elevation of blood alanine and aspartate aminotransferases levels- over 3500 I.U per liter (18). Other symptoms include severe hepatocytes damage, metabolic acidosis, renal insufficiency and damage, coma, thrombocytopenia and pancreatitis (19,20). Such type of hepatotoxicity is aggravated by concomitant use of phenytoin, isoniazid, starvation or chronic alcohol consumption (19,20). The standard antidote for such hepatotoxicity is *N*-acetylcysteine which is highly effective in replenishing the depleted glutathione stores and preventing further hepatic injury even when administered 10 hours following paracetamol ingestion (16,21). Similar glutathione depletion-induced hepatotoxicity is observed following excessive consumption of mescaline and cocaine (22). Other drugs that are shown to induce toxic hepatic damage included the selective serotonin reuptake inhibitor and antidepressant citalopram (23, 24), the macrolide erythromycin analogue roxithromycin (25,26) and the anthraquinone laxatives (27).

With regard to the herbal medicines, many plants have been shown to induce toxic hepatic damage. Table 1 depicts some of the most famous plants that are available as herbal medicines in various pharmaceutical forms. The Table also shows the generic and Latin names of the plant, its active constituents and its purported uses.

b. Allergic hepatic damage:

Allergic hepatic damage is usually caused by the antigen formed via the combination of a hapten of the drug or the active constituent of a herb with a specific liver protein (10,36). The efficacy of such combination to culminate in an active antigen depends upon the human leukocyte antigen (HLA) configuration which is genetically determined (42, 43). The newly formed antigen is then processed by the human macrophages and presented to the CD⁴

cells that initiate the immune response that involves both humoral and cellular immunities. The produced antibodies then bind to the membranes of the hepatocytes. The antigen antibody reaction then results in hepatic damage that is accompanied by skin rash, urticaria, fever, gastrointestinal upset, jaundice and hepatomegaly (10,36).

Several drugs are shown to induce allergic hepatic damage. These include the combination of amoxicillin-clavulanate (42), sulphonamides (42), diphenylhydantoin (44) and the anti HIV-I drug nevirapine (45,46).

With regard to herbal medicines some plants have been shown to induce their hepatotoxicity via this allergic reaction. These include *Illicium lanceolatum* (or Mang Cao), *Lycopodium serratum* (or Jin Bu Huan), *Tripterygium wilfordii* and the Germander herb *Teucrium chamaedrys* (30,31,37, 38). (For constituents and use see also Table-1)

c. Idiosyncratic Hepatotoxicity:

Some of the well established drugs have been reported to induce non-allergic hepatotoxicity that is unpredictable. It is believed to result from metabolic aberrations. The reaction latent period takes from weeks up to months following use of the drug. It can be differentiated from allergic hepatotoxicity by the absence of fever, rash or eosinophilia. Some of the drugs that have been shown to induce such hepatotoxicity are: isoniazid, valproic acid, ketoconazole, methyl dopa and diclofenac (47,48). No reports concerning medicinal herbs are revealed.

d. Hepatic cholestasis:

As mentioned above, one of the liver functions is synthesis of bile salts and their passage into the gall bladder to be secreted into the duodenum. These comprise the salts of the primary bile acids such as cholic and chenodeoxy cholic acids which are conjugated with glycine or taurine and from which the secondary bile acids such as deoxycholic acid, lithocholic acid and ursodeoxycholic acid are formed by the action of the resident bacteria (49). Some drugs have the ability to interrupt bile flow and secretion from the hepatocytes into the gall bladder via binding of the bile salts in the liver or by interaction with the bile salts transporting proteins. This results in the accumulation of the bile inside the liver with the concomitant cholestasis and appearance of high level of bilirubin in the blood and

precipitation of jaundice (10,36). The hepatocytes are usually undamaged. However, if such cholestasis is accompanied by failure of canalicular and other intracellular processes, the toxic bile acids will accumulate within the hepatocytes leading to their damage. The damage may also extend to the bile ducts (50). Thus, mixed hepatotoxicity can ensue (10). In normal hepatic cholestasis, the patient suffers from jaundice together with fever, skin rash and arthralgia with an elevation of ALT enzyme and prolongation of prothrombin time. In the mixed hepatotoxicity one can observe capillary cholangiectasis, reduction in microvilli, formation of microbiliary thrombosis, liver cells degeneration, necrosis and bile sedimentation (10).

Many synthetic widely used drugs are known for their ability to induce hepatic cholestasis of the non-mixed type. These include chlorpromazine, hydrochlorothiazide, tenoxicam, estrogens, erythromycin, ibuprofen, captopril, prochlorperazine, clarithromycin, ticlopidine, terfenadine, amoxicillin-clavulanate, co-trimoxazole, tetrahydrocannabinol and parenteral nutrition (16,22,51,51-54), metformin (55), cyproterone (56), pravastatin (57,58). However, both lovastatin (59) and atorvastatin (60, 61) induce toxic acute hepatitis. Drug-induced mixed hepatic damage is observed following use of metformin, carbamazepine, cyclosporine, amoxicillin-clavulanate, fenofibrate and methimazole (9, 10).

Table 1: Medicinal plants that induce toxic liver damage.

Generic or Trade names	Latin name	Botanical family	Constituents	Purported uses	Reference
Milkwort; Da gin niu cao.	<i>Polygala chinensis</i>	Polygalaceae	Chinensin, chnensina pathol	Sedative.	(28,29)
Germander	<i>Teucrium chamaedrys</i>	Labiatae	Iridoid glycosides; furanoditerpenoids, Celerodane, Neocelerodane, Phenylpropanoids, Teucrin A	Antiobesity	(30,31)
Kava tubers	<i>Piper methysticum</i>	Piperaceae	Kava pyrones, Kavaine alkaloids	Antianxiety Antipsychotic	(32,33)
Impila	<i>Callilepis laureola</i>	Asteraceae	Atracytoloside; Carboxyatracetylolide	Anthelmintic Antitussive Antiimpotence	(34)
Comfrey	<i>Symphytum officinale</i>	Boraginaceae	Pyrrolizidine alkaloids: Symphytine; Intermedine, Echimidine, symglandine	Antigastrointestinal ailments	(35)
Colts foot	<i>Tussilago farfara</i>	Asteraceae	Pyrrolizidine alkaloids: Senkirkine; Senecionine	Treatment of lung and gastric diseases	(36)
Lycopodium herb, Jin Bu Huan	<i>Lycopodium serratum</i>	Lycopodiaceae	Tetrahydropalmatine	Analgesic	(37)
Tripterygium Roots, leaves and flowers	<i>Tripterygium wilfordii</i>	Celasteraceae	Wilforgine; Triptolide	Male contraceptive	(38)
Polygonum herb; Shou Wu Pian	<i>Polygonum multiflorum</i>	Polygonaceae	Anthraquinones	Treatment of prostate cancer, hair loss and re-blackening of gray hair	(39-41)

Table 2. Medicinal plants that induce cholestatic hepatitis.

Generic or Trade names	Latin name	Botanical family	Constituents	Purported uses	References
Chaparral leaves; Creosote bush	<i>Larrea tridentata</i> ; (<i>Larrea divaricata</i> <i>Covillea tridentata</i>)	Zygophyllaceae	Nordihydro- guaiaretic acid	Anti-psoriasis; Anti-amoebic; Diuretic; Antioxidant	(63-65)
Cascara	<i>Rhamnus purshiana</i>	Rhamnaceae	Free Anthraquinones, anthraquinone glycosides	Laxative	(66)
Rhubarb	<i>Rheum cultorum</i>	Polygonaceae	Anthraquinones	Laxative	(67)
Senna leaves	<i>Cassia senna</i>	Fabaceae	Anthraquinone glycosides (Sennosides A and B)	Laxative	(68)
Polygonum Shou Wu Pian	<i>Polygonum multiflorum</i>	Polygonaceae	Anthraquinones	Treatment of prostate cancer	(39-41)

Table 3. Medicinal plants that induce mixed hepatic necrosis and cholestatic hepatitis.

Generic or Trade names	Latin name	Botanical family	Constituents	Purported uses	References
Kava Ka tubers	<i>Piper methysticum</i>	Piperaceae	Alkaloids (Kavaine)	Antianxiety, Antipsychotic	(32,33)
Coutarea herb Copalchi, Copaltra	<i>Coutarea latiflora</i>	Rubiaceae		Treatment of diabetes mellitus Type II	(69)
Ephedra, Ma-Huang	<i>Ephedra sinica</i>	Ephedraceae	Ephedrine & related alkaloids	Anorexigenic to decrease body weight; Treatment of asthma	(70,71)
Polygonum Shou Wu Pian	<i>Polygonum multiflorum</i>	Polygonaceae	Anthraquinones	Treatment of prostate cancer	(39-41)
Aristolochia	<i>Aristolochia bracteata</i>	Aristolochiaceae	Aristolochic acid Magnoflorine	Abortifacient	(72)

With regard to medicinal herbs several plants have been implicated in the induction of cholestatic hepatitis. These are shown in Table 2. Others have been shown to induce mixed hepatic damage necrosis and cholestasis. Some of these are shown in Table 3. In contrast some plants can suppress or treat cholestatic hepatitis. An example of these is *Balanitis aegyptica* bark extract (62).

e. Granulomatous Hepatitis:

Granulomatous hepatitis is characterized by infiltration of inflammatory cells and granulomatous

changes in the hepatic parenchyma and the portal region. There are small rounded foci of epitheloid cells and round cells with multi-nucleated giant cells which may be surrounded by eosinophils. It may be accompanied by low grade fever and chronic fatigue. These symptoms are also present in cases of sarcoidosis and tuberculosis (73). It is now known that chronic use of various drugs induces this type of hepatotoxicity. These include: ticlopidine (74), allopurinol (75), carbamazepine (76,77), aspirin (78), paracetamol (79), dicloxacillin (80), glibenclamide (81), rosiglitazone (82), norfloxacin

(83), nitrofurantoin (84), procainamide (85), mebendazole (86), methimazole (87), phenytoin (88), hydralazine (89), diltiazem (90), methyldopa (91), sulfonamides (92), and amoxicillin-clavulanic acid (93).

With regard to the natural products it has been reported that intake of quinine (94) and quinidine (95) or consumption of ground and squeezed young leaves of barley used as a supplementary nutrient under the generic name "Green juice" induced granulomatous hepatitis with excessive elevation in both AST and ALT enzymes (96).

f. Hepatic Veno-occlusive disease:

Hepatic Veno-occlusive disease results from closure or obliteration of the small intrahepatic veins by loose connective tissues in absence of thrombi. It is a progressive disease that leads to massive hepatocellular necrosis (97). It is usually observed as hepatomegaly, ascites, jaundice and weight gain (97).

With regard to drugs it is usually induced by high doses of some anticancer drugs such as azathioprine, cyclophosphamide, thioguanine and combination of cis-platinum-cyclophosphamide and dicarbazine (98).

Concerning the medicinal herbs, two of them have been reported to induce hepatic venoocclusive disease. The first is the herbal medicine which is known as "Black Cohosh" which composed of an infusion of the herbs *Heliotropium*, *Senecio* and *Crotalaria species*. The major constituents of these herbs are pyrrolizidine alkaloids (99). The second one is the medicinal tea which is known in trade as the Jamaican "Bush Tea". It is composed of an infusion of the medicinal herb Comfrey that is claimed to be an effective treatment for gastrointestinal pain (100). It is known by the Latin name *Symphytum officinale* and contains various pyrrolizidine alkaloids such as symphytine, intermedine, echimidine and symglandin (35).

g. Hepatic phospholipidosis:

Phospholipidosis is a minor hepatic disease that is induced by some amphophilic drugs that have a tendency to accumulate within the lysosomes and interact with their phospholipids resulting in suppression of lysosomal function. It also induces hepatomegaly (101). Amiodarone is one of the drugs known to induce such disturbance (102). There are

no reports about medicinal plants causing this hepatic disturbance.

h. Non-Alcoholic Steatohepatitis:

Non-alcoholic steatohepatitis is usually described as fatty liver with inflammation and necrosis in absence of alcohol consumption. It is believed to be due to excessive release of free fatty acids released from the accumulated hepatic triglycerides. It is accompanied by a decrease in S-adenosyl methionine that protects the liver against fatty degeneration (103,104). It is accompanied by an elevation in hepatic aminotransferases and hepatomegaly and may predispose to liver fibrosis and cirrhosis (105,106). It is usually observed in patients with obesity, diabetes mellitus type 2 or hyperlipidemias and mostly in patients with insulin resistance (104). Various drugs have been shown to induce this disease. These include: amineptine and valproate (107); olanzapine and risperidone (108); tamoxifen (109), corticosteroids [prednisolone (110) and methylprednisolone (111)], amiodarone (106), zidovudine (112), didanosine (2, 3-dideoxyinosine) (113) and high doses of tetracycline and aspirin (106) and parenteral nutrition (53). There are no reports for herbal medicines, to induce this condition.

i. Liver Fibrosis and Cirrhosis:

Some drugs have been shown to induce direct liver fibrosis and cirrhosis without inducing any elevation in hepatic aminotransferases or blood bilirubin. However, portal hypertension may be precipitated. These include high doses of methotrexate (114), methyldopa (115), and vitamin A (116).

With regard to plants, however, various plants that belong to the genus *Senecio*, family Asteraceae e.g. *Senecio aureus*, *S. bicolor* and *S. vulgaris* have been observed to induce liver cirrhosis (117).

j. Liver Tumors:

Sporadic reports point to the involvement of some drugs in inducing hepatic carcinogenicity but there is controversy in this aspect. The accused drugs are methotrexate (118), cyclosporine (119) and nitrofurantoin (120). However, in herbal medicines most of the plants that contain pyrrolizidine alkaloids e.g. heliotrine and indicine have been positively linked with induction of hepatic cancer.

These include those herbs that belong to the genus *Heliotropium*, family Boraginaceae such as *Heliotropium arborescens*, *H. popvii*, *H. lasiocarpium*, *H. eichwaldii*, *H. indicum* and *H. bacciferum* (121) and those plants that belong to the genus *Senecio*, family Asteraceae which are medicinally used for inducing diuresis and diaphoresis. Such as *Senecio aureus*, *S. bicolor*, *S. jacobaco*, *S. vulgaris*, *S. douglasii* and *S. dofonicum*. This *Senecio* genus of herbs contains various pyrrolizidine alkaloids such as senecionine, riddeline, retrorsine, floridanine, monocrotaline and otosenine (121). Other medicinal plants that also induce liver cancer include *Aristolochia bracteata* that belongs to the botanical family Aristolochiaceae and contains aristolochic acid and magnoflorine (72). Others are *Lingularia dentate*, *L. intermedia*, *Crotalaria albida* and *C. tetragona* which belong to the botanical family Asteraceae (121).

Diagnosis of the hepatotoxicity

The initial steps in diagnosis of the drugs and medicinal herbs-induced hepatic damages are (96, 103):

- a- Thorough grasping of the patient's medical history that include the types of drugs and/or herbal medicines used together with their doses frequency and duration of their use.
- b- The medical health of the patient should be considered.
- c- Various biochemical parameters should be measured. These include measurement of blood levels of bilirubin, hepatic transaminases e.g. aspartate aminotransferase (AST) and alanine aminotranferase (ALT) together with γ -glutamyl transpeptidase and alkaline phosphatase enzymes.
- d- All diseases known to induce hepatotoxicity similar to drugs and medicinal herbs-induced hepatotoxicity such as sarcoidosis and tuberculosis should be excluded.
- e- Performance of serological tests to check the presence and absence of the following antibodies:
 - i. IgM antihepatitis A virus
 - ii. Antihepatitis B/and C viruses
 - iii. IgM anticytomegalovirus
 - iv. IgM anti Epstein-Bar virus capsid antigen
 - v. Herpes simplex virus
 - vi. Anti-nuclear
- f- Performance of ultra-sound guided percutaneous liver biopsy.
- g- If possible the response to re-challenge with the suspected drug should be performed.
- vii. Anti-mitochondrial

Besides these, the presence or absence of hepatitis B surface antigen and hepatitis C RNA should be examined.

Treatment of Hepatotoxicity

Generally there is no established treatment for drugs- or herbs-induced hepatotoxicity. The best that can be done is the withdrawal of the offending drug or herb. Beside these, it can be pointed that some benefits have been observed with corticosteroids in allergic hepatotoxicity (10) and with betaine (103), clofibrate and ursodeoxycholic acid (122,123) and metformin (124,125) for non-alcoholic steatohepatitis. Of all of drugs-induced hepatotoxicities, the only one that can be effectively treated is that of paracetamol via use of *N*-acetylcysteine (16, 21).

Concluding Remarks

This review clearly attempted to reveal the seriousness of the problems of drugs and herbal medicines-induced hepatotoxicity and pin pointed the limitations of its treatment. Thus, it remains for the health authorities in various countries to re-consider the registration of all those drugs and all approved medicinal herbs that have been shown in this review and others to induce or even predispose to hepatotoxicity. All of the medications mentioned in this review are not unique. Several of their better substitutes are already registered in various parts of the world. Thus care must be taken when these drugs are used for long times. This should be under the direction of physicians with careful monitoring of liver function.

On a broad basis we as drug informers we have to enlighten the public with the real facts that medicinal herbs do contain both harmful and beneficial chemicals but unfortunately some of them are not well studied, regarding their toxicities and useful doses. Thus we have to advice all those patients who suffer from hepatic renal and cardiovascular diseases to avoid the use of not well studied herbs and all those which are not clearly labeled for their active constituents, accurate doses and uses.

References

1. Porth CM. Pathophysiology: concepts of altered health states 3 rd ed. J.B Lippincott Company, Philadelphia, 1992, p 720.
2. Young LY and Koda-Kimble (eds). Applied Therapeutics: the clinical use of drugs 6th ed. 1995, P 26-1.
3. Begaud B. The liver as the target organ for idiosyncratic reactions In: Idiosyncratic drug reactions: Impact on drug development and clinical use after marketing (Naranjo CA and Jones JK (eds). Elsevier Science, Amsterdam, 1990 pp 85-98.
4. Faich GA. US adverse drug reaction surveillance 1989-1994. Pharmacoepidemiol Drug Safety 1996; 5; 393-8.
5. Bem JL, Breckenridge AM, Mann RD and Rawlins MD. Review of yellow card (1986): a report to the Committee on Safety of Medicines. Br J Clin Pharmacol 1988; 26: 679-90.
6. Pillans PL. Drug associated hepatic reaction in New Zealand: 21 years of experience. N Z Med 1996; 109: 315-9.
7. Wang YZ and Fei JH. Chinese herb-induced liver damage. J Clin Int Med 1998; 15: 179-181.
8. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449-459.
9. Shah RR. Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adverse Drug React Toxicol 1999; 18: 181-233.
10. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 1118-1127.
11. Hunt CM, Westerkam WR, and Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 43: 2407-12.
12. Barent CR, Abbot RA, Bailey CJ, Flatt PR and Ioannides C. Cytochrome P-450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes. Biochem Pharmacol 1992; 43: 1868-71.
13. Nolin TD, Frye RF and Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 2003; 42: 906-925.
14. Farrel GC. Mechanism of halothane induced liver injury. J Gastroenterol Hepatol 1988; 3: 465-482.
15. Mitchell JR, Thorgeirsson SS, and Potter WZ. Acetaminophen induced-hepatic injury, protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther 1997; 18: 676-684.
16. ElTahir KEH. The Pharmacology of Essential Drugs, Alfrzadag Publishing Co. Riyadh 2004, pp 97-8.
17. Prescott LF, and Crtchley JA. Drug interactions affecting analgesic toxicity. Am J Med 1983; 75: 113-116.
18. Schiodt FV, Rochling FJ, Casey DL and Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J MED 1997; 337: 1112-7.
19. Sceff LB, Cuccherini BA, Zimmerman HJ, Alder E and Benjamin SB. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 1986; 104: 399-404.
20. Whitcomb DC and Block GD. Association of hepatotoxicity with fasting and alcohol use. JAMA 1994; 272: 1845-50.
21. Prescott LF, Illingworth RN, Crtchley JAH, Stewart MJ, Adam RD and Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. BMJ 1979; 2: 1097-100
22. ElTahir KEH. Narcotics and Mind-manifesting drugs. Alfrzadag Publishing Co. Riyadh, 2002, pp 70-90.
23. Fredriscon OK and Svendsen O. Hepatotoxicity of citalopram in rats and first pass metabolism. Archiv Toxicol Suppl 1978; 1: 177-180.
24. Lopez-Torres E, Lucena MI, Seoane J, Verge C, Andrade RJ. Hepatotoxicity related to citalopram. Am J Psychiatry 2004; 161: 932-4.
25. Vial T, Biour M, Descotes J, Trepo C. Antibiotic associated hepatitis updated from 1990.. Ann Pharmacother 1997; 31: 204 220.
26. Akeay A, Kanbay M, Sezer S and Ozdemir F. Acute renal failure and hepatotoxicity associated with roxithromycin. Ann Pharmacother 2004; 38: 721-722.
27. Beuers U, Spengler U and Pape GR. Hepatic hepatitis after chronic use of senna. Lancet 1991; 337: 372-373.
28. Ghosal S, Chauhan RPS, Srivastava RS. Chemical constituents of polygalaceae III. Two aryl naphthate lignans from polygla chinensis. Phytochemistry (Elsevier) 19974; 13: 1933-6.
29. Ghosal S, Chauhan RPS, Srivastava RS. Chemical constituents of polygalaceae III. Structure of chinensin a new lignan lactone from polygala chinensis. Phytochemistry 1994; 13: 2281-4
30. Lalibere L and Villeneuve JP. Hepatitis after use of germander: an herbal remedy. Can Med Assoc J 1996; 154: 1689-1692.
31. Stickel F, Egerer G and Seitz HK. Hepatotoxicity of botanicals. Pub Health Nutr 2000; 3: 113-124.
32. Russmann S, Lauterbury BH and Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-69.
33. Moulds RF and Malani J. Kava: herbal panacea or liver poison? Med J Aust 2003; 178: 451-3.
34. Popat A, Shear NH, Malkiewicz I, Stewart MJ, Steenkamp V, Thomson S and Neuman MG. The toxicity of *Callilepis Laureola*: a South African traditional herbal medicine. Clin Biochem 2001; 34: 229-36.
35. Yuan JL. Current studies on Chinese herb-induced liver diseases. Chinese Herbs 1999; 30: 711-726.
36. Ridker PM, Ohkuma S, Mcdermott MV, Trey C and Huxtable RJ. Hepatic venoocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88: 1050-1054.
37. Picciotto A, Campo N and Brizzolara R. Chronic hepatitis induced by Jin Bu Huan. J Hepatology 1998; 28: 165-167.
38. Liao LQ. Tentative analogues of Chinese-herb-induced liver damage. J Integrated Chinese Western Medicine on Liver disease 2001; 11: 60-62.
39. But PP, Tomlinson B and Lee KI. Hepatitis related to Chinese medicine Shou-Wu-Pian manufactured from *Polygonum multiflorum*. Vet Hum Toxicol 1996; 38:280-282.
40. Park GJ, Mann SP and Ngu MC. Acute hepatitis induced by Shou-Wu-Pia, a herbal product derived from *Polygonum multiflorum*. J Gastroenterol Hepatol 2001, 16: 115-117.
41. Battinelli L, Danuele C, Mazzant G, Mastroianni CM, Lichtner M, Coletta S and Costantini S. New case of acute hepatitis following the consumption of Sou-Wu-Pian, a Chinese herbal product derived from *Polygonum multiflorum*. Ann Internal Med 2004; 140: 589-590.
42. Hautekeete MI, Horsmans Y, Van Waey-enberge C, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PS, Rahier J and Geubel AP. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117: 1181-6.

43. Pohl LR. Drug-induced allergic hepatitis. *Semin Liver Dis* 1990; 10: 305-15.
44. Kleckner HB, Yakulis V and Heller P. Severe hypersensitivity to diphenhydantoin with circulating antibodies to drug. *Ann Intern Med* 1975; 83: 522-3.
45. Baylor MS and Johann-Liang R. Hepatotoxicity associated with nevirapine use. *Acquir Immune Defic Synd* 2004; 35: 538-539.
46. WHO. Regulatory and safety action. *Drug information* 2004; 18:31.
47. Garibaldi RA, Drusin RE, Fercbee SH and Gregg MB. Isoniazid-associated hepatitis, report of an out-break. *Am Rev Respir Dis* 1972; 106: 357-65.
48. Ramakrishana B and Viswanath N. Diclofenac-induced hepatitis: case report and literature review. *Liver* 1994; 14: 83-4.
49. Diem K and Lentener C (eds). *Scientific Tables*; Seventh edition. Ciba-Geigy Limited, Basle, Switzerland 1970, pp 653-56.
50. Trauner M, Meler PJ and Boyer J. Molecular pathogenesis of cholestasis. *N Engl J Med* 1998; 339: 1217-27.
51. Chitturi S, and Farrell GC. Drug-induced cholestasis. *Semin Gastrointest Dis* 2001; 12: 113-4
52. Velayudham LS, and Farrell GC. Drug-induced cholestasis. *Expert Opin Drug Saf* 2003; 2: 287-304.
53. Fulford A, Scolapio JS and Aranda-Michel J. Parenteral nutrition-association hepatotoxicity. *Nutr Clin Pract* 2004; 19: 274-283.
54. Mindikoglu AL, Anantharaju A, Hartman GG, Li SD, Villanueva J and Van Thiel DH. Prochlorperazine-induced cholestasis in patients with alpha-1-antitrypsin deficiency. *Hepatogastroenterology* 2003; 50: 1338-40.
55. Desilets D J, Shorr AF, Moran KA and Holtzmuller KC. Cholestatic jaundice associated with use of metformin. *Am J Gastroenterol* 2001; 96: 2257-2258.
56. Anon. High dose cyproterone and hepatotoxicity. *Aust Adv Drug Reactions Bull* 2004; 23: 3.
57. Hartleb M, Rymerczyk G, and Januszewski K. Acute cholestatic hepatitis associated with pravastatin. *Am J Gastroenterol* 1999; 94: 1388-1390.
58. Bolego C, Baetta R, Bellosta S, Corsini A, and Paoletti R. Safety consideration for statins. *Current Opinion Lipidol* 2002; 13: 637-44.
59. Gimbert S, Pessayre D, Degott C and Benhamou JP. Acute hepatitis induced by MG-Co-A reductase inhibitor, lovastatin. *Dig Dis Sci* 1994; 39: 2032-33.
60. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atrovastatin-induced acute hepatitis with absence of cross-sensitivity with simvastatin. *Lancet* 1999; 353: 1763-1764.
61. Chalsani N, Aljadhey H, Kesterson J, Murray MD and Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology* 2004; 126: 128-1292.
62. Mohamed AH, ElTahir KEH, Ali MB, Galal M, Ageel IA and Hamid OA. Some pharmacological and toxicological studies on *Balanitis aegyptica* bark. *Phytotherapy Res* 1999; 13: 1-3.
63. Alderman S, Kailas S, Goldfarb S, Singaram C and Malone DG. Cholestasis hepatitis after ingestion of chaparral leaf: Confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy. *J Clin Gastroenterol* 1994; 19: 242-247.
64. Sheikh NM, Philen RM, and Love LA. Chaparral-associated hepatitis. *Archiv Intern Med* 1997; 157: 913-919.
65. Batchelor WB, Heathcote J and Wanless IR. Chaparral-induced hepatic injury. *Am J Gastroenterol* 1995; 90: 831-832.
66. Nadir A, Reddy D and Van Thiel DH. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension. Case report and review of herbal hepatotoxicity. *Am J Gastroenterol* 2000; 95: 3634-37.
67. Streicher G. Acute renal failure and jaundice following rhubarb leaf poisoning. *Dtsch Med Wochenschr* 1994; 89: 2379-2381.
68. D' Arcy PF. Hepatitis after chronic use of senna. *Int Pharm J* 1991; 5: 106.
69. Wurtz AS, Vial T, Isoard B and Saillard E. Possible hepatotoxicity from Copaltra an herbal medicine. *Ann Pharmacother* 2002; 36: 941-942.
70. Nadir A., Agarwal S, King PD and Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product Ma-Huang. *Am J Gastroenterol* 1996; 91: 1436-1438.
71. US Food and Drug Administration. Dietary supplements containing ephedrine alkaloids. Withdrawal in part, 65 Federal Register 17477 year 2000.
72. ElTahir KEH. Pharmacological actions of magnoflorine and aristolochic acid-1 isolated from seeds of *Aristolochia bracteata*. *Int J Pharmacogn* 1991; 29: 1-11.
73. McMaster KR 3rd and Henniger GR. Drug-induced granulomatous hepatitis. *Lab Invest* 1981; 44: 61-73.
74. Ruiz-Valverde P, Zafon C, Segarra A, Ribera R and Piera L. Ticlopidine-induced granulomatous hepatitis. *Ann Pharmacother* 1995; 29: 633-4.
75. Swank LA, Chejfee G and Nemchausky BA. Allopurinol induced granulomatous hepatitis with cholangitis and sarcoid-like reaction. *Arch Intern Med* 138: 997-998.
76. Forbes GM, Jeffery GP, Shilkin KB and Reed WD. Carbamazepine hepatotoxicity: another cause of vanishing bile duct syndrome. *Gastroenterology* 102: 1385-8.
77. Swinburn BA, Croxson MS, Miller MV and Crawford KB. Carbamazepine induced granulomatous hepatitis. *N Z Med J* 1986; 99: 167.
78. Elzouki AN and Lindgren S. Granulomatous hepatitis induced by aspirin-codeine analgesics. *J Intern Med* 1996; 239: 279-81.
79. Lindgren A, Aldenborg F, Norkrans G, Olaison L and Olsson R. Paracetamol-induced cholestatic and granulomatous liver injuries. *J Intern Med* 1997; 241: 435-9.
80. Saab S, Venkataramani A and Yao F. Possible granulomatous hepatitis after dicloxacillin therapy. *J Clin Gastroenterol* 1996; 22: 163-4.
81. Saw D, Pitman E, Maung M, Savasatit P, Wasserman D and Yeung CK. Granulomatous hepatitis associated with glyburide. *Dig Dis Sci* 1996; 41: 322-5.
82. Dhawan M, Agrawal R, Ravi J, Gulati S, Silverman J, Nathan G and Raab S. Rosiglitazone-induced granulomatous hepatitis. *J Clin Gastroenterol* 2002; 34: 582-4
83. Bjoruss E, Olsson R and Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. *Am J Gastroenterol* 2000; 95: 3662-4.
84. Sippel PJ and Agger WA. Nitrofurantoin-induced granulomatous hepatitis. *Urology* 1981; 18: 177-8.
85. Rotmensch HH, Yust I, Siegman-Igra Y, Liron M, Ilie B and Vardinon N. Granulomatous hepatitis: a hypersensitivity response to procainamide. *Ann Intern Med* 1978; 89: 646-7.

86. Colle I, Naegels S, Hoorens A and Hautekeete M. Granulomatous hepatitis due to mebendazole. *J Clin Gastroenterol* 1999; 28: 44-5.
87. Di Gregorio C, Ghini F and Rivasi F. Granulomatous hepatitis in a patient receiving methimazole. *Ital J Gastroenterol* 1990; 22: 75-7.
88. Cook IF, Shilkin KB and Reed WD. Phenytoin induced granulomatous hepatitis. *Aust N Z Med* 1981; 11: 539-41.
89. Rice D and Burdick CO. Granulomatous hepatitis from hydralazine therapy. *Arch Intern Med* 1983; 143: 1077.
90. Toft E, Vyberg M and Therkelsen K. Diltiazem-induced granulomatous hepatitis. *Histopathology* 1991; 18: 474-5.
91. Mirada Canals A, Monteagudo Jimenez M, Sole Villa J and Rodriguez Moreno C. Methylodopa-induced granulomatous hepatitis. *DICP* 1991; 25: 1269-70.
92. Fich A, Schwartz J, Braverman D, Zifroni A and Rachmilewitz D. Sulfasalazine hepatotoxicity. *Am J Gastroenterol* 1984; 79: 401-2.
93. Silvain C, Fort E, Levillain P, Labat-Labourdette J and Beauchant M. Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. *Dig Dis Sci* 1992; 37: 150-2.
94. Katz B, Weetch M and Chopra S. Quinine-induced granulomatous hepatitis. *Br Med J* 1983; 286: 264-5.
95. Geltner D, Chajek T, Rubinger D and Levij IS. Quinidine hypersensitivity and liver involvement: A survey of 32 patients. *Gastroenterology* 1976; 70: 650-2.
96. Mifuji R, Iwasa M, Tanaka Y, Hori Y, Araki J, Kaito M and Adachi Y. "Green juice" associated granulomatous hepatitis. *Am J Gastroenterol* 2003; 98: 2334-2335.
97. Rollins BJ. Hepatic veno-occlusive disease. *Am J Med* 1986; 81: 297-306.
98. Lemley DE, Delacy LM, Seeff LB, Ishak KG and Nashel DJ. Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis. *Ann Rheum Dis* 1989; 48: 342-346.
99. Whiting PW, Clouston A and Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. *Med J Aust* 2002; 177: 440-443.
100. Bach N, Thung SN and Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. *Am J Med* 1989; 87: 97-99.
101. Halliwell WH. Cationic amphiphilic drug induced phospholipidosis. *Toxicol Pathol* 1997; 25: 53-60.
102. Reasor MJ, and Kacew S. Drug-induced phospholipidosis: are those functional consequences. *Exp Biol Med* 2001; 226: 825-30.
103. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB and Lindor KD. Betaine, a promising new agent for patients with non-alcoholic steatohepatitis: Results of Pilot Study. *Am J Gastroenterol* 2001; 96: 2711-14.
104. Lee RG. Non-alcoholic steatohepatitis. A study of 49 patients. *Hum Pathol* 1989; 6: 594-598.
105. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ. Non-alcoholic fatty acid disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999; 116: 1413-19.
106. Stravitz RT, and Sanyal AJ. Drug-induced steatohepatitis. *Clin Liver Dis* 2003; 7: 435-51.
107. Lonardo A. Fatty liver and non-alcoholic steatohepatitis: where do we stand and where are we going. *Dig Dis* 1999; 17: 80-89.
108. Haberfellner M and Honsig T. Non-alcoholic steatohepatitis: a possible side effect of atypical antipsychotics. *J Clin Psychiatry* 2003; 64: 851.
109. Nemoto Y, Saibra T, Ogawa Y, Zhang T, Xu W, Ono M, Akisawa N, Iwasaki S, Maeda T and Onishi S. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. *Intern Med* 2002; 41: 345-50.
110. Dourakis SP, Sevastianos VA, and Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. *Am J Gastroenterol* 2002; 97: 1074-75.
111. Candelli M, Nista EC, Pignataro G, Zannoni G, de Pascalis B, Gasbarrini G and Gasbarrini A. Steatohepatitis during methylprednisolone therapy for ulcerative colitis. *J Int Med* 2003; 253: 391-392.
112. Gardon JD, Chapnick EK, Sepkowitz DV. Zidovudine-induced hepatitis. *J Intern Med* 1992; 231: 317-8.
113. Lai KK, Gang DL, Zawack JK and Cools TP. Fulminant hepatic failure associated with 2,3 dideoxyinosine (ddI). *Ann Intern Med* 1991; 115: 283-4.
114. Gilbert SC, Klintmalm G, Menter A, and Silverman A. Methotrexate-induced cirrhosis in three patients with psoriasis: a word of caution in light of expanding use of this "steroid sparing" agent. *Arch Intern Med* 1990; 150: 889-891.
115. Lee WN and Dalton WT. Chronic hepatitis and indolent cirrhosis due to methylodopa: the bottom of iceberg? *JSC Med Assoc* 1989; 85:75-9.
116. Geubal AP, Galocsy C, Alves N, Rahier J and Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. *Gastroenterology* 1991; 100: 1701-9.
117. Wilmot FC and Robertson GW. Senecio disease or cirrhosis of liver due to senecio poisoning. *Lancet* 1920; 2: 848-9.
118. Mehdi A, Marteau P, Lavergne A, Molho-Sabatier P, Cochand-Priollet B, Caen J, and Rambaud JC. Hepatocellular carcinoma in a patient with psoriasis and methotrexate-induced cirrhosis. *Gastroenterol Clin Biol* 1991; 15: 464-465.
119. Honda H, Franken EA Jr, Barloom TJ and Smith JL. Hepatic lymphoma in cyclosporine-treated transplant recipients sonographic and CT findings. *Am J Roentgenol* 1989; 152: 501-3.
120. Anttinen H, Ahonen A, Leinonen A, Kallioinen M and Heikkinen ES. Diagnostic imaging of focal nodular hyperplasia of the liver developing during nitrofurantoin therapy. *Acta Med Scan* 1982 211: 227-32.
121. Fu PP, Yang YC, Xia QS, Chou MW, Cui YY and Lin G. Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements. *J Food and Drug Analysis* 2002; 10 (4): 198-211.
122. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, and McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. *Hepatology* 1996; 23: 1464-1467.
123. Bauditz J, Schmidt HH, Dippe P, Lochs H and Pirlich M. Non-alcoholic induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid *Am J Gastroenterol* 2004; 99: 959-60.
124. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M and Melchionda N. Metformin in non-alcoholic steatohepatitis. *Lancet* 2001; 358: 893-894.
125. Urso R and Visco-Comandini U. Metformin in non-alcoholic steatohepatitis. *Lancet* 2002; 359: 355-356.